Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Clinical trial NCT01356849 · COMPLETED
Trial details
- NCT number
- NCT01356849
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-01
- Primary completion
- 2012-08-01
- Enrollment
- 149
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.